1-3 of 3
Henry Maseruka
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cumulative Efficacy and Safety of 5-Year Deferasirox (Exjade ® ) Treatment in Pediatric Patients with Thalassemia Major: A Phase II Multicenter Prospective Trial

Antonio Piga, Kamila Kebaili, Renzo Galanello, Valentine Jehl, Corinne Rebischung, Henry Maseruka, Lisa Rojkjaer, Gian Luca Forni
Journal: Blood
Blood (2008) 112 (11): 5413.
https://doi.org/10.1182/blood.V112.11.5413.5413
Published: 2008
Journal Articles

Long-Term Efficacy and Safety with Deferasirox (Exjade®, ICL670), a Once-Daily Oral Iron Chelator, in Pediatric Patients.

Antonio Piga, Elliott Vichinsky, Gian Luca Forni, Yurdanur Kilinc, Henry Maseruka, Antonios Kattamis
Journal: Blood
Blood (2007) 110 (11): 2774.
https://doi.org/10.1182/blood.V110.11.2774.2774
Published: 2007
Journal Articles

Once-Daily Treatment with the Oral Iron Chelator ICL670 (Exjade®): Results of a Phase II Study in Pediatric Patients with β-Thalassemia Major.

Antonio Piga, MD, Renzo Galanello, MD, Maria Loreta Foschini, MD, Antonella Zappu, MD, Elena Bordone, MD, Filomena Longo, MD, Gian-Luca Forni, MD, Antonella Lavagetto, MD, Yves Bertrand, MD, Henry Maseruka, PhD, Nicola Latham, MSc, Daniele Alberti, MD
Journal: Blood
Blood (2004) 104 (11): 3614.
https://doi.org/10.1182/blood.V104.11.3614.3614
Published: 2004